[Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].

Tomoyuki Irino, Tomohisa Egawa, Takeshi Kenmochi, Yasuhiro Ito, Koki Mihara, Akihiko Okamura, Eiichi Eto, Yusaku Inaba, Masaaki Murakawa, Atsushi Nagashima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

There is no standard approach for second-line chemotherapy after a failure of the first-line regimen, fluorouracil and cisplatin -based chemotherapy in patients with unresectable or recurrent esophageal cancer. We have treated with biweekly nedaplatin (CDGP 40 mg/m2) in combination with docetaxe (l DOC 30 mg/m2) as second-line chemotherapy and investigated its efficacy and safety. Fifteen patients were retrospectively assessed in this study. Response rate (RR) and disease control rate (DCR) were 0 and 6.7%, respectively. Median time to progression( TTP) and median survival time( MST) were 2.1 and 7.0 months. Neutropenia and thrombocytopenia of grade 3 were seen in 4 (26.7%) and 1 (6.7%) patients, but no other serious adverse effects were detected. Based on the results, a biweekly nedaplatin/docetaxel regimen was safely received on an outpatient basis but not enough to provide a significant survival benefit. Quality of life and minimization of adverse effects are key considerations in second-line chemotherapy. Thereby, future trials should assess a quality of life in conjunction with different combination of active drugs and doses.

Original languageEnglish
Pages (from-to)2401-2404
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume38
Issue number12
Publication statusPublished - 2011 Jan 1
Externally publishedYes

Fingerprint

docetaxel
Esophageal Neoplasms
Safety
Drug Therapy
Quality of Life
Survival
Drug Combinations
Neutropenia
Fluorouracil
Cisplatin
Outpatients
nedaplatin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

[Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer]. / Irino, Tomoyuki; Egawa, Tomohisa; Kenmochi, Takeshi; Ito, Yasuhiro; Mihara, Koki; Okamura, Akihiko; Eto, Eiichi; Inaba, Yusaku; Murakawa, Masaaki; Nagashima, Atsushi.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 38, No. 12, 01.01.2011, p. 2401-2404.

Research output: Contribution to journalArticle

Irino, T, Egawa, T, Kenmochi, T, Ito, Y, Mihara, K, Okamura, A, Eto, E, Inaba, Y, Murakawa, M & Nagashima, A 2011, '[Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 38, no. 12, pp. 2401-2404.
Irino, Tomoyuki ; Egawa, Tomohisa ; Kenmochi, Takeshi ; Ito, Yasuhiro ; Mihara, Koki ; Okamura, Akihiko ; Eto, Eiichi ; Inaba, Yusaku ; Murakawa, Masaaki ; Nagashima, Atsushi. / [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer]. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2011 ; Vol. 38, No. 12. pp. 2401-2404.
@article{8936f72dace74f2f9ec6361d9c902480,
title = "[Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].",
abstract = "There is no standard approach for second-line chemotherapy after a failure of the first-line regimen, fluorouracil and cisplatin -based chemotherapy in patients with unresectable or recurrent esophageal cancer. We have treated with biweekly nedaplatin (CDGP 40 mg/m2) in combination with docetaxe (l DOC 30 mg/m2) as second-line chemotherapy and investigated its efficacy and safety. Fifteen patients were retrospectively assessed in this study. Response rate (RR) and disease control rate (DCR) were 0 and 6.7{\%}, respectively. Median time to progression( TTP) and median survival time( MST) were 2.1 and 7.0 months. Neutropenia and thrombocytopenia of grade 3 were seen in 4 (26.7{\%}) and 1 (6.7{\%}) patients, but no other serious adverse effects were detected. Based on the results, a biweekly nedaplatin/docetaxel regimen was safely received on an outpatient basis but not enough to provide a significant survival benefit. Quality of life and minimization of adverse effects are key considerations in second-line chemotherapy. Thereby, future trials should assess a quality of life in conjunction with different combination of active drugs and doses.",
author = "Tomoyuki Irino and Tomohisa Egawa and Takeshi Kenmochi and Yasuhiro Ito and Koki Mihara and Akihiko Okamura and Eiichi Eto and Yusaku Inaba and Masaaki Murakawa and Atsushi Nagashima",
year = "2011",
month = "1",
day = "1",
language = "English",
volume = "38",
pages = "2401--2404",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].

AU - Irino, Tomoyuki

AU - Egawa, Tomohisa

AU - Kenmochi, Takeshi

AU - Ito, Yasuhiro

AU - Mihara, Koki

AU - Okamura, Akihiko

AU - Eto, Eiichi

AU - Inaba, Yusaku

AU - Murakawa, Masaaki

AU - Nagashima, Atsushi

PY - 2011/1/1

Y1 - 2011/1/1

N2 - There is no standard approach for second-line chemotherapy after a failure of the first-line regimen, fluorouracil and cisplatin -based chemotherapy in patients with unresectable or recurrent esophageal cancer. We have treated with biweekly nedaplatin (CDGP 40 mg/m2) in combination with docetaxe (l DOC 30 mg/m2) as second-line chemotherapy and investigated its efficacy and safety. Fifteen patients were retrospectively assessed in this study. Response rate (RR) and disease control rate (DCR) were 0 and 6.7%, respectively. Median time to progression( TTP) and median survival time( MST) were 2.1 and 7.0 months. Neutropenia and thrombocytopenia of grade 3 were seen in 4 (26.7%) and 1 (6.7%) patients, but no other serious adverse effects were detected. Based on the results, a biweekly nedaplatin/docetaxel regimen was safely received on an outpatient basis but not enough to provide a significant survival benefit. Quality of life and minimization of adverse effects are key considerations in second-line chemotherapy. Thereby, future trials should assess a quality of life in conjunction with different combination of active drugs and doses.

AB - There is no standard approach for second-line chemotherapy after a failure of the first-line regimen, fluorouracil and cisplatin -based chemotherapy in patients with unresectable or recurrent esophageal cancer. We have treated with biweekly nedaplatin (CDGP 40 mg/m2) in combination with docetaxe (l DOC 30 mg/m2) as second-line chemotherapy and investigated its efficacy and safety. Fifteen patients were retrospectively assessed in this study. Response rate (RR) and disease control rate (DCR) were 0 and 6.7%, respectively. Median time to progression( TTP) and median survival time( MST) were 2.1 and 7.0 months. Neutropenia and thrombocytopenia of grade 3 were seen in 4 (26.7%) and 1 (6.7%) patients, but no other serious adverse effects were detected. Based on the results, a biweekly nedaplatin/docetaxel regimen was safely received on an outpatient basis but not enough to provide a significant survival benefit. Quality of life and minimization of adverse effects are key considerations in second-line chemotherapy. Thereby, future trials should assess a quality of life in conjunction with different combination of active drugs and doses.

UR - http://www.scopus.com/inward/record.url?scp=84858830889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858830889&partnerID=8YFLogxK

M3 - Article

C2 - 22202395

AN - SCOPUS:84858830889

VL - 38

SP - 2401

EP - 2404

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -